Velcade

bortezomib

Velcade

Pharmacologic class: Proteasome inhibitor

Therapeutic class: Antineoplastic

Pregnancy risk category D

Action

Inhibits proteasomes (enzyme complexes that regulate protein homeostasis within cells). Reversibly inhibits chymotrypsin-like activity at 26S proteasome, leading to activation of signaling cascades, cell-cycle arrest, and apoptosis.

Availability

Powder for reconstitution (preservative-free): 3.5 mg (contains 35 mg of mannitol)

Indications and dosages

Multiple myeloma, patients with mantle cell lymphoma who have received at least one prior therapy

Adults: 1.3 mg/m2 I.V. or subcutaneously twice weekly for 2 weeks (days 1, 4, 8, and 11), followed by 10-day rest period (days 12 to 21). Allow at least 72 hours to elapse

between doses. One treatment cycle equals 21 days (3 weeks).

Dosage adjustment

• Moderate or severe hepatic impairment

• Peripheral neuropathy

• Grade 3 nonhematologic events

• Grade 4 hematologic events

Contraindications

• Hypersensitivity to drug, mannitol, or boron

Precautions

Use cautiously in:

• peripheral neuropathy, dehydration, hepatic or renal impairment

• history of syncope or cardiovascular disorders

• pregnant or breastfeeding patients

• children.

Administration

• Be aware that drug is for I.V. or subcutaneous use only. Because each route of administration has a different reconstituted concentration, use caution when calculating volume to be administered.

• Reconstitute drug in vial with 3.5 ml of normal saline for injection to yield a concentration of 1 mg/ml for I.V. use.

• Reconstitute drug in vial with 1.4 ml of normal saline for injection to yield a concentration of 2.5 mg/ml for subcutaneous use.

• Give by I.V. push over 3 to 5 seconds or subcutaneously.

• Reconstituted solution must be used within 8 hours.

Adverse reactions

CNS: headache, insomnia, dizziness, anxiety, peripheral neuropathy, reversible posterior leukoen-cephalopathy syndrome

CV: tachycardia, hypotension

EENT: throat tightness

GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia

Hematologic: eosinophilia, anemia, thrombocytopenia, neutropenia

Hepatic: hyperbilirubinemia, hepatitis, acute liver failure

Metabolic: dehydration, pyrexia

Respiratory: cough, dyspnea, upper respiratory tract infection, acute diffuse infiltrative pulmonary disease (pneumonitis, interstitial pneumonia, acute respiratory distress syndrome)

Skin: rash, pruritus, urticaria

Other: altered taste, increased or decreased appetite, fever, chills, edema, tumor lysis syndrome

Interactions

Drug-drug. CYP3A4 inducers (including amiodarone, carbamazepine, nevi-rapine, phenobarbital, phenytoin, and rifampin): possible decrease in bortezomid serum level and efficacy

CYP3A4 inhibitors (including amiodarone, cimetidine, clarithromycin, delavirdine, diltiazem, disulfiram, erythromycin, fluoxetine, fluvoxamine, nefazodone, nevirapine, propoxyphene, quinupristin, verapamil, zafirlukast, and zileuton): possible increase in bortezomib serum level and efficacy

Drug-diagnostic tests. Liver function

tests: increased levels

Drug-food. Grapefruit juice: increased bortezomib blood level, greater risk of toxicity

Patient monitoring

Monitor vital signs and temperature. Especially watch for tachycardia, fever, and hypotension.

Stay alert for and discontinue drug if posterior leukoencephalopathy (headache, seizures, lethargy, confusion, blindness) or tumor lysis syndrome occurs (irregular heartbeat, shortness of breath, high potassium level, high uric acid level, impairment of mental ability, kidney failure).

Closely monitor liver function tests and watch for signs and symptoms of hepatitis or liver failure.

• Monitor nutritional and hydration status for changes caused by GI adverse effects.

• Monitor CBC with white cell differential, and watch for signs and symptoms of blood dyscrasias.

Monitor respiratory status, watching for dyspnea, cough, and other signs and symptoms of upper respiratory tract infection.

Patient teaching

Inform patient that drug can cause serious blood dyscrasias. Teach him which signs and symptoms to report right away.

• Tell patient that drug may cause other significant adverse reactions. Reassure him he will be closely monitored.

• Instruct patient to move slowly when sitting or standing up to avoid dizziness or light-headedness from sudden blood pressure drop.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• Advise patient to minimize adverse GI effects by eating small frequent servings of healthy food and ensuring adequate fluid intake.

• Tell patient to immediately report signs and symptoms of upper respiratory tract infection.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

bortezomib

A proteasome inhibitor which induces apoptosis in cancer cells, and inhibits binding to stromal cells and production of growth and survival factors.

Indications
Treatment-refractory myeloma (35% response rate), mantle cell lymphoma.
 
Adverse effects
Thrombocytopaenia, fatigue, peripheral neuropathy, neutropaenia. 

Velcade

A brand name for BORTEZOMIB.

Patient discussion about Velcade

Q. Has anyone out there taken the new drug Velcade?????? I've just started a JNJ Valcade trial and wonder if anyone out there has any experience this chemo treatment.

A. for a year and 2 months now. she is in pain but still alive and functioning.

More discussions about Velcade
References in periodicals archive ?
--Raising full year guidance to reflect divestitures and revised VELCADE Loss of Exclusivity (LOE) assumption
The ongoing, randomized Phase 3 BOSTON study evaluating selinexor in combination with Velcade and low-dose dexamethasone will serve as the confirmatory trial.
The Janssen Pharmaceutical Companies reported on Monday the receipt of approval from the US Food and Drug Administration (FDA) for DARZALEX (daratumumab) in combination with VELCADE (bortezomib), melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma.
Curtis also brings substantial sales and marketing acumen gained through his involvement in several oncology treatments, including Doxil, Velcade, and Tykerb.
Takeda has its own track record of oncology product launches, including Adcetris (Brentuximab Vedotin), Ninlaro (ixazomib) and Velcade (bortezomib).
The resulting Journal of Pathology study showcased mice suffering from a form of bone marrow cell cancer called multiple myeloma, which were treated with a selective drug called Velcade. Shaked and his team discovered that the drug actually enhanced the cancer's resistance to treatment over time, making it stronger and more aggressive.
The current global market size for standard of care treatments, including Revlimid and Velcade, is over USD 8 billion.
Additionally, the extension of indications of several already marketed drugs such as Revlimid as a maintenance therapy for DLBCL, Velcade as a front-line therapy for MCL and Adcetris as front-line therapy for CD30 T-cell lymphoma, will fuel the growth during the forecast period.
Third-party product (TPP) sales contracted by 19% y-o-y, as tenders under 7 nosologies federal program did not take place (namely, auctions for Velcade, which contributed 62% to TPP sales in 1Q12).
Bortezomib (Velcade) was approved in 2003, and has had an important role in prolonging the lives of patients with this cancer.
(Osaka JPN) are recalling batches of their Velcade blood-cancer medicine in the U.K., U.S.
Thalidomide and Velcade (bortezomib) will be made available for some patients with multiple myeloma, according to the National Institute Health and Clinical Excellence (Nice).